RAIN,TNGX,TYRA Stock Price and Quote

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: TOMZ CLIR LIQT BCHT SCWO ARQ ZONE PCT YDDL CWST

| Held by: VXF VTI CHNA

Index	-
Market Cap	18.93M
Enterprise Value	30.54M
Income	-9.47M
Sales	0.01M
Book/sh	-1.75
Cash/sh	0.06
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	24
IPO	Jan 02, 2025

P/E	-
Forward P/E	-
PEG	-
P/S	1892.91
P/B	-
P/C	32.64
P/FCF	-
EV/EBITDA	-
EV/Sales	3053.91
Quick Ratio	0.07
Current Ratio	0.07
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-1.20
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-1098.00%
Sales Y/Y TTM	-
EPS Q/Q	-20.68%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	99.41%
Insider Trans	0.42%
Inst Own	9.15%
Inst Trans	16.58%
ROA	-479.60%
ROE	-
ROIC	-
Gross Margin	-175.50%
Oper. Margin	-78440.73%
Profit Margin	-90182.27%
SMA20	-10.22%
SMA50	-9.32%
SMA200	-49.17%
Trades

Shs Outstand	8.13M
Shs Float	0.06M
Short Float	78.98%
Short Ratio	1.26
Short Interest	0.05M
52W High	8.52 -78.52%
52W Low	1.26 45.15%
Volatility	8.36% 14.81%
ATR (14)	0.27
RSI (14)	42.45
Beta	-0.24
Rel Volume	0.62
Avg Volume	37.53K
Volume	23,392

Perf Week	-7.58%
Perf Month	-16.44%
Perf Quarter	-31.20%
Perf Half Y	-51.97%
Perf YTD	-68.66%
Perf Year	-44.88%
Perf 3Y	-82.49%
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	1.92
Price	1.83
Change	-4.69%

Jun-09-26 09:30AM	Rain Enhancement Technologies Reports WETA Delivers New Water at $10 Per Acre-Foot, a Fraction of the Cost of Conventional Supply Alternatives (ACCESSWIRE)
May-11-26 11:00AM	One Additional Inch of Rainfall from Ground-Based Rain Enhancement Worth $44 Million Annually to 37 Texas Counties, Texas A&M Analysis Finds (ACCESSWIRE) +14.96%
Apr-27-26 09:30AM	Rain Enhancement Technologies Introduces Industry-First Guaranteed 10% Precipitation Enhancement (ACCESSWIRE)
Apr-03-26 12:11PM	Rain City Resources Announces Revocation of Management Cease Trade Order (TMX Newsfile)
Mar-31-26 09:30AM	Rain Enhancement Technologies Reports Consistent Snowpack Enhancement Across Three-Month Winter Operations in Utah (ACCESSWIRE) -5.93%
08:09PM	Loading…
Mar-26-26 08:09PM	Rain City Resources Provides Update on Management Cease Trade Order (TMX Newsfile)
Feb-26-26 01:02PM	Rain City Resources Provides Update on Management Cease Trade Order (TMX Newsfile)
Feb-18-26 10:00AM	Singular Research Emerging Growth & Value Leaders Webinar Thursday, February 19, 2026 (TMX Newsfile) -7.75%
Feb-12-26 08:00AM	Rain Enhancement Technologies Reports More Than 20% Snowpack Enhancement in Utah During January Operations (ACCESSWIRE)
Feb-05-26 08:00AM	Rain Enhancement Technologies Expands Research into Air Quality and Smog Mitigation (ACCESSWIRE)
Dec-18-25 11:45AM	Rain Enhancement Technologies Appoints David Sylvester, CFO of Steelcase, to Board of Directors (ACCESSWIRE) +9.64%
Dec-16-25 10:00AM	Rain Enhancement Technologies Reports Early Positive Indications From First Two U.S. Installations (ACCESSWIRE)
Nov-18-25 10:00AM	Rain Enhancement Technologies Secures Second U.S. Installation with Utah Permit Approval, Advances Snow Enhancement Capabilities (ACCESSWIRE) -17.56%
Nov-11-25 09:10AM	Rain Enhancement Technologies Launches First U.S. Installation with Colorado Permit Approval (ACCESSWIRE) +10.34%
Nov-07-25 09:00AM	Rain Enhancement Technologies Holdco, Inc. Regains Compliance with Nasdaq Listing Requirements (ACCESSWIRE)
10:00AM	Loading…
Oct-30-25 10:00AM	Rain Enhancement Technologies Exhibits at Premier WMO Scientific Conference, Showcases Ionization Research Advancements (ACCESSWIRE)
Oct-28-25 10:00AM	Rain Enhancement Technologies Reports Promising Results from Australia Fog Mitigation Pilot, Plans Expanded US Testing (ACCESSWIRE)
Oct-15-25 10:00AM	Rain Enhancement Technologies Strengthens Strategic Leadership with Quantum Physics Pioneer and Corporate Governance Expert (ACCESSWIRE) +8.63%
Sep-18-25 10:00AM	Rain Enhancement Technologies Assembles World-Class Technical Advisory Board to Advance Weather Enhancement Innovation (ACCESSWIRE) -11.98%
Aug-22-25 04:30PM	RAIN ENHANCEMENT TECHNOLOGIES HOLDCO, INC. RECEIVES AND APPEALS NASDAQ DELISTING NOTICE (GlobeNewswire) +8.45%
Aug-20-25 09:20AM	Rain Enhancement Technologies Announces Fog Mitigation Pilot in Australia (ACCESSWIRE)
08:00AM	Dot Ai Welcomes Two New Directors to Support Next Phase of Growth (Business Wire)
Aug-12-25 09:20AM	Rain Enhancement Technologies Strengthens Board of Directors with Appointment of Industry Veterans Bob Reardon and Marc Peperzak (ACCESSWIRE)
Aug-07-25 11:50AM	Rain Enhancement Technologies Announces Appointment of Scott Morris as Senior Technical Advisor (ACCESSWIRE)
Feb-03-25 08:00AM	Rain Enhancement Technologies Holdco, Inc. Announces Management Updates and Appointment of Randy Seidl as Chief Executive Officer (Business Wire)

Rain Enhancement Technologies Holdco, Inc. develops, manufactures, and commercializes ionization rainfall generation technology to provide additional rainfall for industries, supranational organizations, countries, and localities. The company is headquartered in Naples, FL.

CEO & DirectorMr. Randall P. Seidl

Chief Financial OfficerMs. Oanh Do Ngoc Truong

Chief Technical OfficerMr. Scott Morris

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DICKERSON LYMAN B	Director	Sep 12 '25	Sale	5.78	4,787	27,669	10,247	Sep 17 08:34 PM
DICKERSON LYMAN B	Director	Sep 09 '25	Sale	5.24	1,917	10,045	15,647	Sep 17 08:34 PM
DICKERSON LYMAN B	Director	Sep 11 '25	Sale	5.80	398	2,308	15,034	Sep 17 08:34 PM
DICKERSON LYMAN B	Director	Sep 10 '25	Sale	5.55	215	1,193	15,432	Sep 17 08:34 PM

TNGX Tango Therapeutics Inc monthly Stock Chart

Peers: CGON KYMR NUVL BMRN INCY RYTM APGE KRYS AXSM NBIX

| Held by: IWM XBI VTI IWO IBB VXF SCHA VTWO FESM DWAS

Index	RUT
Market Cap	4.97B
Enterprise Value	4.62B
Income	-107.23M
Sales	56.99M
Book/sh	2.72
Cash/sh	2.33
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	137
IPO	Sep 03, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	87.19
P/B	11.24
P/C	13.08
P/FCF	-
EV/EBITDA	-
EV/Sales	81.10
Quick Ratio	27.38
Current Ratio	27.38
Debt/Eq	0.08
LT Debt/Eq	0.08
Option/Short	Yes / Yes

EPS (ttm)	-0.82
EPS next Y	-1.54
EPS next Q	-0.32
EPS this Y	-49.43%
EPS next Y	-18.53%
EPS next 5Y	-24.36%
EPS past 3/5Y	10.79% 11.68%
Sales past 3/5Y	35.89% 52.13%
EPS Y/Y TTM	32.40%
Sales Y/Y TTM	39.04%
EPS Q/Q	12.31%
Sales Q/Q	-100.00%
Earnings	May 13 AMC
EPS/Sales Surpr.	-2.01% -100.00%

Insider Own	26.72%
Insider Trans	-0.67%
Inst Own	88.87%
Inst Trans	1.12%
ROA	-30.20%
ROE	-38.42%
ROIC	-25.44%
Gross Margin	96.28%
Oper. Margin	-206.22%
Profit Margin	-188.15%
SMA20	0.79%
SMA50	18.59%
SMA200	92.65%
Trades

Shs Outstand	144.16M
Shs Float	119.32M
Short Float	28.53%
Short Ratio	8.05
Short Interest	34.04M
52W High	34.39 -11.25%
52W Low	5.75 430.78%
Volatility	5.82% 7.12%
ATR (14)	2.09
RSI (14)	56.45
Beta	1.15
Rel Volume	0.65
Avg Volume	4.23M
Volume	2,747,064

Perf Week	6.23%
Perf Month	-1.33%
Perf Quarter	52.14%
Perf Half Y	215.62%
Perf YTD	244.47%
Perf Year	405.30%
Perf 3Y	856.74%
Perf 5Y	179.56%
Perf 10Y	-
Recom	1.17
Target Price	43.82
Prev Close	30.64
Price	30.52
Change	-0.39%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-26-26	Upgrade	Jefferies	Hold → Buy	$60
Jun-08-26	Upgrade	Wolfe Research	Peer Perform → Outperform
May-15-26	Downgrade	Piper Sandler	Overweight → Neutral	$24
May-14-26	Downgrade	Jefferies	Buy → Hold	$27
Apr-02-26	Initiated	Canaccord Genuity	Buy	$30
Feb-23-26	Initiated	Mizuho	Outperform	$19
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Aug-19-25	Initiated	Piper Sandler	Overweight	$11
Jul-17-24	Initiated	Jefferies	Buy	$19
Apr-04-24	Initiated	Cantor Fitzgerald	Overweight
Feb-12-24	Initiated	Piper Sandler	Overweight	$18
Dec-08-23	Initiated	B. Riley Securities	Buy	$16
Oct-20-22	Upgrade	H.C. Wainwright	Neutral → Buy	$10
Sep-20-21	Initiated	SVB Leerink	Outperform	$25

Show Previous Ratings

Jun-26-26 03:38PM	This Biotech ETF Has Almost Doubled in 13 Months. Money Is Flowing In. (Barrons.com)
Jun-22-26 04:05PM	Tango Therapeutics Appoints Robert Azelby to Board of Directors (GlobeNewswire)
Jun-11-26 03:56PM	Imviva Unveils Leukemia Data at EHA 2026 With 86% Response Rates (Exec Edge)
Jun-09-26 10:49PM	Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering (GlobeNewswire) -9.13%
09:32AM	Tango Therapeutics stock surges on pancreatic cancer drug combo data (Quartz)
09:31AM	Loading…
09:31AM	Tango Therapeutics stock surges on pancreatic cancer trial data (Quartz)
Jun-08-26 04:09PM	Tango Skyrockets On Eye-Popping Pancreatic Cancer Results (Investor's Business Daily) +52.97%
04:01PM	Tango Therapeutics Announces Proposed $500 Million Public Offering (GlobeNewswire)
02:28PM	?? Under the Radar: Tango Stock Climbs on Positive Pancreatic Cancer Data (The Wall Street Journal)
01:44PM	TNGX Stock Hits All-Time High Wolfe Research Calls Tango Therapeutics Pancreatic Cancer Trial Data Groundbreaking (Stocktwits)
12:28PM	Tango Therapeutics Stock Soars 42% After 'Unprecedented' Data on Pancreatic Cancer Treatment (Barrons.com)
06:59AM	Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer (GlobeNewswire)
Jun-05-26 07:00AM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.71%
May-13-26 04:07PM	Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights (GlobeNewswire) +8.55%
May-04-26 04:31PM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.25% +6.56%
08:03AM	Loading…
Apr-30-26 08:03AM	Why This CEO Is Confident His Drug Can Top 'Unprecedented' Pancreatic Cancer Results (Investor's Business Daily)
Apr-15-26 09:05AM	Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat (GlobeNewswire) +5.28%
Mar-10-26 08:03AM	Wedbush Reaffirms Outperform Rating for Tango Therapeutics (TNGX) (Insider Monkey)
Mar-09-26 11:15AM	X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention (24/7 Wall St.)
Mar-07-26 08:20PM	Tango Therapeutics (TNGX) Soars 52% on Buy Reco (Insider Monkey)
Mar-06-26 05:33PM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:45AM	TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS (Zacks)
Mar-05-26 08:13PM	Tango Therapeutics (TNGX) Hits All-Time High as Analyst Turns Bullish (Insider Monkey) +36.28%
04:13PM	Tango Therapeutics, Up 39% This Year, Surges Again On Another Cancer Pact (Investor's Business Daily)
07:00AM	Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
Mar-04-26 07:18AM	Earnings To Watch: Tango Therapeutics Inc (TNGX) Reports Q4 2025 Result (GuruFocus.com) +7.39%
Feb-26-26 09:38AM	RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View (Zacks) -9.74%
Feb-18-26 07:00AM	Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Feb-15-26 02:02PM	Tango Therapeutics CEO Teases Pivotal Vopimetostat Trial, RAS Combo Data at Guggenheim Chat (MarketBeat)
Feb-03-26 07:00AM	Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire) +5.11%
09:05AM	Loading…
Jan-08-26 09:05AM	Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor (GlobeNewswire) -6.23%
Jan-07-26 03:33PM	Revolution Medicines stock surges over 20% on potential AbbVie acquisition (Investing.com) +21.92%
Jan-05-26 07:00AM	Tango Therapeutics Appoints Sung Lee to Board of Directors (GlobeNewswire)
Dec-22-25 08:10AM	3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 (Zacks)
Dec-17-25 02:19PM	5 Biotech Stocks to Watch for Potential Upside (Zacks)
07:00AM	Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-25 10:47AM	Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance (PR Newswire)
Dec-08-25 09:55AM	Can Tango Therapeutics (TNGX) Climb 37.28% to Reach the Level Wall Street Analysts Expect? (Zacks)
Nov-26-25 07:00AM	Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-21-25 07:45PM	Novavax, UniFirst, and More Stocks See Action From Activist Investors (Barrons.com) +12.70%
09:55AM	Wall Street Analysts See a 46.07% Upside in Tango Therapeutics (TNGX): Can the Stock Really Move This High? (Zacks)
Nov-12-25 07:00AM	Tango Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference (GlobeNewswire) -8.47%
Nov-04-25 10:15AM	Tango Therapeutics, Inc. (TNGX) Tops Q3 Earnings and Revenue Estimates (Zacks)
09:00AM	Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
Nov-03-25 07:46AM	Tango Therapeutics Inc (TNGX) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-31-25 09:55AM	Wall Street Analysts Think Tango Therapeutics (TNGX) Could Surge 52.2%: Read This Before Placing a Bet (Zacks)
Oct-29-25 07:00AM	Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 (GlobeNewswire)
Oct-27-25 12:00PM	Tango Therapeutics (TNGX) Upgraded to Buy: Here's Why (Zacks)
Oct-23-25 07:20AM	Tango Therapeutics Announces $225 Million Financing (GlobeNewswire) -13.05%
07:00AM	Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers (GlobeNewswire)
Oct-06-25 07:00AM	Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025 (GlobeNewswire)
Sep-17-25 09:27AM	Tango Therapeutics (TNGX) Soars 7.8%: Is Further Upside Left in the Stock? (Zacks)
Aug-26-25 07:00AM	Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-19-25 09:32AM	Palo Alto upgraded, Li Auto downgraded: Wall Street's top analyst calls (The Fly)
Aug-05-25 08:15AM	Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
Aug-04-25 09:53AM	Tango Therapeutics Inc (TNGX) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Jul-31-25 07:40PM	IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates (Zacks) +8.11%
Jul-30-25 10:00AM	Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
09:55AM	Wall Street Analysts Believe Tango Therapeutics (TNGX) Could Rally 61.46%: Here's is How to Trade (Zacks)
Jul-29-25 10:00AM	Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-22-25 07:00AM	Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 (GlobeNewswire)
Jul-14-25 09:55AM	Does Tango Therapeutics (TNGX) Have the Potential to Rally 75.89% as Wall Street Analysts Expect? (Zacks)
Jun-30-25 05:47AM	Tango doses first subject in MTAP-deleted and RAS mutant cancer trial (Clinical Trials Arena)
Jun-27-25 07:00AM	Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer (GlobeNewswire)
Jun-23-25 09:07AM	Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last? (Zacks)
May-27-25 07:00AM	Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire) +11.41%
May-21-25 07:00AM	Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors (GlobeNewswire) -8.70%
May-12-25 08:15AM	Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +14.91%
07:00AM	Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
May-09-25 09:45AM	Tango Therapeutics Inc (TNGX) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
May-06-25 08:20AM	Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -11.27%
May-05-25 10:00AM	Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks) -5.96%
May-01-25 07:00AM	Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 (GlobeNewswire)
Apr-09-25 05:00AM	Barbara Weber, M.D., Elected to ITM Supervisory Board (GlobeNewswire) +16.53%
Mar-25-25 04:30PM	Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire) -5.75% -6.10%
Feb-27-25 07:00AM	Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights (GlobeNewswire) -6.44%
Feb-20-25 07:30AM	Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences (GlobeNewswire)
Jan-30-25 07:00AM	Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference (GlobeNewswire)
Dec-03-24 07:00AM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.14%
Nov-27-24 07:00AM	Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference (Business Wire) +6.25%
Nov-23-24 10:26AM	Tango Therapeutics Inc. (TNGX): Among the Most Promising Cancer Stocks According to Hedge Funds (Insider Monkey)
Nov-06-24 07:05AM	Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights (Business Wire) -37.45%
07:00AM	Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program (Business Wire)
Aug-28-24 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Aug-18-24 09:03AM	Jefferies Predicts up to 270% Rally for These 2 Strong Buy Stocks (TipRanks)
Aug-07-24 07:00AM	Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights (Business Wire)
Jun-14-24 05:10AM	Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last? (Zacks) +6.44%
Jun-05-24 07:00AM	Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-23-24 09:18AM	Medivirs licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program (PR Newswire)
07:00AM	Tango Therapeutics Announces Discontinuation of TNG348 Program (Business Wire)
May-08-24 01:53PM	TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:10AM	Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights (Business Wire)
May-07-24 10:00AM	Will Tango Therapeutics, Inc. (TNGX) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-01-24 04:48PM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-20-24 05:31AM	Tango Therapeutics Inc (TNGX) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
Mar-18-24 02:52PM	TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -7.09%
08:10AM	Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights (Business Wire)

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, Antoni Ribas and Barbara Weber in 2017 and is headquartered in Boston, MA.

Founder & Executive Chairman of the BoardDr. Barbara L. Weber M.D.

PresidentDr. Malte Peters M.D.

Executive OfficerMs. Daniella Beckman CPA

Ph.D.Dr. Adam S. Crystal M.D.

Ph.D.Prof. Alan Ashworth FRS

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Crystal Adam	President, R&D	Jul 01 '26	Option Exercise	5.20	27,000	140,400	142,743	Jul 02 07:23 PM
Crystal Adam	President, R&D	Jul 01 '26	Sale	29.59	27,000	798,908	115,743	Jul 02 07:23 PM
Nextech Crossover I SCSp	Former Affiliate	Jun 17 '26	Proposed Sale	30.10	3,766,081	113,359,038		Jun 17 04:45 PM
DANIELLA BECKMAN	Officer	Jun 11 '26	Proposed Sale	28.76	1,791,726	51,523,582		Jun 11 06:00 PM
DANIELLA BECKMAN	Officer	Jun 10 '26	Proposed Sale	30.00	4,446	133,380		Jun 10 04:45 PM
Crystal Adam	President, R&D	Jun 01 '26	Option Exercise	5.20	27,000	140,400	142,743	Jun 03 06:37 PM
Crystal Adam	President, R&D	Jun 01 '26	Sale	22.87	27,000	617,571	115,743	Jun 03 06:37 PM
Crystal Adam	President, R&D	May 01 '26	Option Exercise	5.20	27,000	140,400	142,743	May 05 07:47 PM
Crystal Adam	President, R&D	May 01 '26	Sale	21.23	27,000	573,097	115,743	May 05 07:47 PM
ADAM CRYSTAL	Officer	May 01 '26	Proposed Sale	21.62	65,460	1,415,245		May 01 04:48 PM
Crystal Adam	President, R&D	Apr 15 '26	Option Exercise	5.20	38,460	199,992	151,082	Apr 16 08:14 PM
Crystal Adam	President, R&D	Apr 15 '26	Sale	25.00	38,460	961,500	112,622	Apr 16 08:14 PM
Crystal Adam	President, R&D	Apr 01 '26	Option Exercise	5.20	27,000	140,400	139,622	Apr 02 08:09 PM
Crystal Adam	President, R&D	Apr 01 '26	Sale	21.20	27,000	572,478	112,622	Apr 02 08:09 PM
Crystal Adam	President, R&D	Mar 25 '26	Option Exercise	5.20	12,000	62,400	124,622	Mar 27 08:06 PM
Crystal Adam	President, R&D	Mar 25 '26	Sale	20.11	12,000	241,320	112,622	Mar 27 08:06 PM
ADAM CRYSTAL	Officer	Mar 25 '26	Proposed Sale	19.48	93,000	1,811,640		Mar 25 04:24 PM
Crystal Adam	President, R&D	Mar 05 '26	Sale	15.00	20,251	303,765	112,622	Mar 09 04:01 PM
ADAM CRYSTAL	Officer	Mar 05 '26	Proposed Sale	12.35	20,251	250,100		Mar 05 04:52 PM
Crystal Adam	President, R&D	Feb 25 '26	Sale	12.77	54,345	694,208	132,873	Feb 27 06:54 PM
ADAM CRYSTAL	Officer	Feb 25 '26	Proposed Sale	12.88	54,345	699,964		Feb 25 04:36 PM
Beckman Daniella	Chief Financial Officer	Feb 03 '26	Sale	12.26	10,317	126,531	184,297	Feb 04 08:12 PM
Weber Barbara	Director, Executive Chair	Feb 03 '26	Sale	12.26	30,519	374,294	1,629,254	Feb 04 08:09 PM
Crystal Adam	President, R&D	Feb 03 '26	Sale	12.26	18,452	226,300	187,218	Feb 04 08:02 PM
Third Rock Ventures IV, L.P.	10% Owner	Oct 23 '25	Sale	10.15	477,401	4,846,575	13,386,574	Oct 27 04:15 PM
Third Rock Ventures IV, L.P.	10% Owner	Oct 23 '25	Proposed Sale	7.53	477,401	3,594,830		Oct 23 05:10 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 25 '25	Sale	8.02	500,000	4,008,500	13,863,975	Sep 29 04:15 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 25 '25	Proposed Sale	7.80	500,000	3,900,000		Sep 25 04:58 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 16 '25	Sale	7.04	363,541	2,559,329	14,363,975	Sep 17 06:06 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 16 '25	Proposed Sale	7.35	363,541	2,672,026		Sep 17 10:29 AM
Third Rock Ventures IV, L.P.	10% Owner	Sep 05 '25	Sale	7.00	642,906	4,500,342	14,813,975	Sep 09 04:15 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 08 '25	Sale	7.04	86,459	608,628	14,727,516	Sep 09 04:15 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 08 '25	Proposed Sale	7.04	86,459	608,628		Sep 08 05:22 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 05 '25	Proposed Sale	6.94	642,906	4,461,767		Sep 05 06:08 PM
Third Rock Ventures IV, L.P.	10% Owner	Aug 22 '25	Sale	7.00	302,194	2,115,358	15,456,881	Aug 26 04:15 PM
Third Rock Ventures IV, L.P.	10% Owner	Aug 22 '25	Proposed Sale	6.90	302,194	2,085,139		Aug 22 05:26 PM
Third Rock Ventures IV, L.P.	10% Owner	Aug 19 '25	Sale	7.01	1,100,000	7,712,760	15,759,075	Aug 21 04:15 PM
Third Rock Ventures IV, L.P.	10% Owner	Aug 19 '25	Proposed Sale	6.96	1,100,000	7,656,000		Aug 19 07:25 PM

TYRA Tyra Biosciences Inc monthly Stock Chart

Peers: IDYA TNGX KYMR NUVL INCY RYTM APGE BMRN KRYS AXSM

| Held by: XBI IWM VTI IWO IBB VXF SCHA VTWO USVM FESM

Index	RUT
Market Cap	1.96B
Enterprise Value	1.59B
Income	-131.10M
Sales	0.00M
Book/sh	6.52
Cash/sh	6.45
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	87
IPO	Sep 15, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	5.07
P/C	5.12
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	20.49
Current Ratio	20.49
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-2.17
EPS next Y	-2.83
EPS next Q	-0.65
EPS this Y	-29.08%
EPS next Y	-9.22%
EPS next 5Y	-13.96%
EPS past 3/5Y	-15.07% -55.76%
Sales past 3/5Y	- -
EPS Y/Y TTM	-33.07%
Sales Y/Y TTM	-
EPS Q/Q	-34.19%
Sales Q/Q	-
Earnings	May 13 BMO
EPS/Sales Surpr.	-8.83% -

Insider Own	25.70%
Insider Trans	-0.20%
Inst Own	88.04%
Inst Trans	14.10%
ROA	-34.71%
ROE	-36.87%
ROIC	-33.38%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	10.41%
SMA50	4.48%
SMA200	20.46%
Trades

Shs Outstand	59.47M
Shs Float	44.18M
Short Float	22.33%
Short Ratio	10.19
Short Interest	9.87M
52W High	40.65 -18.79%
52W Low	9.93 232.43%
Volatility	5.34% 6.57%
ATR (14)	1.83
RSI (14)	60.14
Beta	0.76
Rel Volume	0.63
Avg Volume	968.28K
Volume	612,240

Perf Week	12.24%
Perf Month	23.40%
Perf Quarter	-11.10%
Perf Half Y	25.04%
Perf YTD	25.56%
Perf Year	223.31%
Perf 3Y	122.59%
Perf 5Y	-
Perf 10Y	-
Recom	1.20
Target Price	50.73
Prev Close	32.57
Price	33.01
Change	1.35%

Date	Action	Analyst	Rating Change	Price Target Change
May-19-26	Initiated	Wolfe Research	Peer Perform
Apr-15-26	Initiated	Guggenheim	Buy	$54
Apr-06-26	Initiated	Canaccord Genuity	Buy	$50
Feb-24-26	Initiated	Cantor Fitzgerald	Overweight
Feb-10-26	Initiated	William Blair	Outperform
Jan-28-26	Initiated	Barclays	Overweight	$59
Sep-03-25	Initiated	Raymond James	Strong Buy	$35
May-21-25	Resumed	Piper Sandler	Overweight	$33
Jan-07-25	Initiated	UBS	Buy	$28
Oct-18-24	Upgrade	BofA Securities	Neutral → Buy	$22 → $31
Aug-15-24	Initiated	Piper Sandler	Overweight	$33
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral	$25 → $15
Jun-30-23	Initiated	Wedbush	Outperform	$27
Feb-03-23	Initiated	Oppenheimer	Outperform	$17
Jun-23-22	Initiated	H.C. Wainwright	Buy	$12
Mar-08-22	Upgrade	Jefferies	Hold → Buy	$31 → $27
Nov-08-21	Downgrade	Jefferies	Buy → Hold
Oct-11-21	Initiated	Jefferies	Buy	$19
Oct-11-21	Initiated	Cowen	Outperform
Oct-11-21	Initiated	BofA Securities	Buy	$22

Show Previous Ratings

May-21-26 08:00AM	TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY (PR Newswire)
May-13-26 08:00AM	Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights (PR Newswire)
May-07-26 04:05PM	Tyra Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Apr-17-26 08:00AM	Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors (PR Newswire)
Mar-02-26 04:05PM	Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights (PR Newswire)
02:11AM	Loading…
02:11AM	Tyra Biosciences Narrows Dabogratinib Focus, Teases Mid-Year NMIBC and 2H Achondroplasia Data (MarketBeat)
Feb-23-26 05:30PM	Tyra Biosciences Announces Poster Presentations at the 2026 ASCO Genitourinary (GU) Cancers Symposium (PR Newswire) +5.45%
Feb-19-26 04:05PM	Tyra Biosciences to Participate in Upcoming Investor Conferences (PR Newswire) +6.56%
Feb-14-26 09:05AM	Tyra Biosciences price target raised to $53 from $37 at Wedbush (TipRanks)
Dec-01-25 08:00AM	Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer (PR Newswire) -7.76%
Nov-12-25 04:05PM	Tyra Biosciences Announces Participation at Upcoming Investor Events (PR Newswire)
Nov-05-25 04:05PM	Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights (PR Newswire)
Aug-22-25 05:38AM	Tyra Biosciences initiates paediatric study for achondroplasia treatment (Clinical Trials Arena)
Aug-21-25 08:00AM	Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia (PR Newswire) +14.26%
Aug-20-25 04:05PM	Tyra Biosciences Announces Participation at Upcoming Investor Events (PR Newswire)
09:55AM	Loading…
Aug-19-25 09:55AM	Wall Street Analysts See a 178.82% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High? (Zacks) -5.64%
Aug-14-25 04:05PM	Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights (PR Newswire)
Jul-21-25 04:05PM	Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series (PR Newswire)
Jul-08-25 04:05PM	Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 (PR Newswire)
Jun-30-25 08:00AM	Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) (PR Newswire) +5.16%
May-12-25 04:05PM	Tyra Biosciences to Participate at Upcoming Investor Conferences (PR Newswire)
May-08-25 04:05PM	Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights (PR Newswire) +10.30%
Mar-27-25 04:05PM	Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights (PR Newswire) -5.66%
Feb-11-25 04:05PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
Jan-29-25 04:05PM	Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors (PR Newswire)
Jan-22-25 08:00AM	Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
Jan-10-25 08:00AM	Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302) (PR Newswire)
Nov-13-24 04:05PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
Nov-07-24 04:05PM	Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights (PR Newswire) -6.06%
Oct-28-24 07:00AM	Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301) (PR Newswire) -9.30%
06:05PM	Loading…
Oct-24-24 06:05PM	Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC) (PR Newswire) -23.35%
Oct-23-24 04:05PM	Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET (PR Newswire)
Oct-22-24 09:07PM	RA Capital Management, L.P. Reduces Stake in Tyra Biosciences Inc (GuruFocus.com)
Oct-18-24 02:34PM	BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug (Benzinga) +5.20%
Oct-16-24 01:01AM	Boxer Capital, LLC Increases Stake in Tyra Biosciences Inc (GuruFocus.com) +5.89%
Oct-11-24 08:00AM	Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) (PR Newswire)
Sep-11-24 04:05PM	Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference (PR Newswire) -5.22%
Sep-10-24 04:05PM	Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer (PR Newswire)
Sep-09-24 09:55AM	Wall Street Analysts Think Tyra Biosciences (TYRA) Could Surge 27.88%: Read This Before Placing a Bet (Zacks)
Aug-27-24 07:50PM	Tyra Biosciences, Inc. (TYRA): One of Oppenheimers Top Stock Picks For the Next 12 Months (Insider Monkey)
Aug-07-24 11:54PM	TYRA Stock Earnings: Tyra Biosciences Beats EPS for Q2 2024 (InvestorPlace)
04:05PM	Tyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights (PR Newswire)
Jul-02-24 04:05PM	Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH) (PR Newswire)
Jun-07-24 12:00PM	Tyra Biosciences (TYRA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:55AM	Wall Street Analysts See a 27.27% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High? (Zacks)
May-23-24 04:05PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
May-09-24 10:54PM	TYRA Stock Earnings: Tyra Biosciences Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights (PR Newswire)
May-07-24 04:05PM	Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors (PR Newswire)
Mar-19-24 09:53PM	TYRA Stock Earnings: Tyra Biosciences Misses EPS for Q4 2023 (InvestorPlace) +7.89%
09:01PM	Tyra Biosciences Inc (TYRA) Reports Increased R&D Investments Amid Pipeline Progress (GuruFocus.com)
04:05PM	Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights (PR Newswire)
Mar-05-24 11:27PM	Insider Sell: Tyra Biosciences Inc (TYRA) COO Daniel Bensen Sells 9,152 Shares (GuruFocus.com)
Mar-01-24 12:40AM	Insider Sell: Tyra Biosciences Inc (TYRA) COO Daniel Bensen Sells 8,644 Shares (GuruFocus.com)
Feb-27-24 04:05PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
Feb-07-24 04:05PM	Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference (PR Newswire)
03:12AM	President and CEO Todd Harris Sells 100,000 Shares of Tyra Biosciences Inc (TYRA) (GuruFocus.com)
Feb-02-24 08:00AM	Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing (PR Newswire) +29.29%
Feb-01-24 05:30PM	Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia (PR Newswire)
Dec-29-23 06:45AM	16 Most Promising Long-Term Stocks According to Analysts (Insider Monkey)
Dec-22-23 09:00AM	Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300 (PR Newswire)
Nov-08-23 04:05PM	Tyra Biosciences to Participate in 2023 Jefferies London Healthcare Conference (PR Newswire)
Nov-07-23 04:05PM	Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights (PR Newswire) -5.00%
Sep-21-23 08:00AM	Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings (PR Newswire)
Sep-12-23 04:05PM	Tyra Biosciences to Participate at 2023 Cantor Global Healthcare Conference (PR Newswire)
Aug-10-23 04:05PM	Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights (PR Newswire)
Aug-01-23 08:00AM	Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA-300 for the Treatment of Achondroplasia (PR Newswire)
Jun-16-23 08:50AM	Here's What Could Help Tyra Biosciences, Inc. (TYRA) Maintain Its Recent Price Strength (Zacks) +6.25%
Jun-07-23 09:55AM	Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 52.22%: Read This Before Placing a Bet (Zacks) -5.63%
May-25-23 08:00AM	Tyra Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
May-23-23 08:50AM	What Makes Tyra Biosciences, Inc. (TYRA) a Good Fit for 'Trend Investing' (Zacks)
May-22-23 09:55AM	Wall Street Analysts Believe Tyra Biosciences, Inc. (TYRA) Could Rally 59.17%: Here's is How to Trade (Zacks)
Apr-09-23 09:30AM	Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation (Simply Wall St.)
Mar-29-23 04:05PM	Tyra Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Mar-27-23 08:50AM	Here's Why 'Trend' Investors Would Love Betting on Tyra Biosciences, Inc. (TYRA) (Zacks)
Mar-22-23 04:05PM	Tyra Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights (PR Newswire) -5.01%
Mar-01-23 08:40AM	Should You Buy Tyra Biosciences (TYRA) Ahead of Earnings? (Zacks)
07:00AM	Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia (PR Newswire)
Feb-22-23 04:05PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire) -7.99% -9.04%
Nov-29-22 07:00AM	Tyra Biosciences Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300 (PR Newswire)
Nov-24-22 09:55AM	How Much Upside is Left in Tyra Biosciences, Inc. (TYRA)? Wall Street Analysts Think 184% (Zacks)
Nov-10-22 04:20PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
Nov-08-22 09:55AM	Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 179%: Read This Before Placing a Bet (Zacks)
Nov-03-22 04:05PM	Tyra Biosciences Reports Third Quarter 2022 Financial Results and Highlights (PR Newswire) -7.00%
Nov-02-22 04:05PM	Tyra Biosciences Announces Planned Chief Financial Officer Transition (PR Newswire)
Oct-31-22 09:22AM	We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth (Simply Wall St.)
Oct-13-22 08:00AM	Tyra Biosciences to Present Preclinical Data on TYRA-200, an FGFR1/2/3 Inhibitor, at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (PR Newswire) +5.46%
Sep-08-22 04:05PM	Tyra Biosciences to Participate at September 2022 Investor Conferences (PR Newswire) +8.24%
Sep-05-22 08:15AM	Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress (PR Newswire)
Aug-04-22 04:05PM	Tyra Biosciences Reports Second Quarter 2022 Financial Results and Highlights (PR Newswire) +14.97%
May-24-22 08:55AM	Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation (Simply Wall St.) -5.68%
May-05-22 04:05PM	Tyra Biosciences Reports First Quarter 2022 Financial Results and Highlights (PR Newswire)
Mar-03-22 04:05PM	Tyra Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights (PR Newswire) -10.21%
Feb-22-22 04:05PM	Tyra Biosciences to Participate in Cowen 42nd Annual Healthcare Conference (PR Newswire)
Dec-21-21 06:38PM	Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ... (GuruFocus.com) +14.48%
Dec-15-21 09:29AM	Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Nov-10-21 04:05PM	Tyra Biosciences to Present at the 2021 Jefferies London Healthcare Conference (PR Newswire)
Nov-03-21 04:05PM	Tyra Biosciences Reports Third Quarter 2021 Financial Results and Highlights (PR Newswire) +19.92% +8.25%
Sep-22-21 08:22AM	3 Stocks Insiders Are Buying (Benzinga) -7.11%
Sep-20-21 07:52AM	3 Stocks Insiders Are Buying (Benzinga) -6.83%

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SNAP, enables the rapid and precise refinement of structural design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.

Co-FounderDr. Todd Harris Ph.D.

Chief Operating OfficerMr. Bhavesh Ashar M.B.A.

Chief Medical OfficerDr. Douglas Warner M.D.

Co-Founder & Chief Discovery OfficerMr. Daniel Bensen

Chief Financial OfficerMr. Alan Fuhrman CPA

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
NEXTECH VI ONCOLOGY SCSP	Shareholder	Jun 26 '26	Proposed Sale	30.94	308,379	9,541,246		Jun 26 04:59 PM
NEXTECH VI ONCOLOGY SCSP	Shareholder	Jun 01 '26	Proposed Sale	33.41	300,000	10,023,000		Jun 01 04:16 PM
Daniel Bensen	Officer	May 12 '26	Proposed Sale	34.25	8,000	274,000		May 12 05:33 PM
Daniel Bensen	Officer	Apr 13 '26	Proposed Sale	35.62	8,000	285,000		Apr 13 04:44 PM
KAPLAN GILLA	Director	Mar 25 '26	Option Exercise	2.25	14,295	32,164	42,526	Mar 27 04:44 PM
KAPLAN GILLA	Director	Mar 25 '26	Sale	36.97	14,295	528,506	28,231	Mar 27 04:44 PM
GILLA KAPLAN	Director	Mar 26 '26	Proposed Sale	37.75	53,172	2,007,153		Mar 26 04:04 PM
GILLA KAPLAN	Director	Mar 25 '26	Proposed Sale	36.97	14,295	528,506		Mar 25 05:36 PM
Daniel Bensen	Officer	Mar 12 '26	Proposed Sale	35.38	8,000	283,000		Mar 12 05:42 PM
Bensen Daniel	Chief Discovery Officer	Feb 12 '26	Sale	32.87	8,000	262,965	146,981	Feb 13 04:30 PM
Daniel Bensen	Officer	Feb 12 '26	Proposed Sale	32.75	8,000	262,000		Feb 12 04:52 PM
Bensen Daniel	Chief Discovery Officer	Jan 12 '26	Sale	28.52	8,000	228,186	154,981	Jan 20 04:30 PM
Daniel Bensen	Officer	Jan 12 '26	Proposed Sale	29.00	8,000	232,000		Jan 12 05:38 PM
MORE ROBERT J	Director	Dec 19 '25	Sale	25.00	10,000	250,000	3,823,425	Dec 19 09:00 PM
Bensen Daniel	Chief Discovery Officer	Dec 12 '25	Sale	22.64	8,000	181,159	162,981	Dec 16 04:30 PM
Daniel Bensen	Officer	Dec 12 '25	Proposed Sale	22.50	8,000	180,000		Dec 12 04:21 PM
MORE ROBERT J	Director	Nov 21 '25	Sale	20.25	246,871	5,000,026	3,833,425	Nov 25 05:00 PM
Alta Partners NextGen Fund II,	Affiliate	Nov 21 '25	Proposed Sale	21.00	256,871	5,394,291		Nov 21 04:26 PM
Bensen Daniel	Chief Operating Officer	Nov 18 '25	Sale	16.07	75,633	1,215,627	220,937	Nov 19 07:30 PM
Bensen Daniel	Chief Operating Officer	Nov 19 '25	Sale	16.32	49,956	815,297	170,981	Nov 19 07:30 PM
Daniel Bensen	Officer	Nov 18 '25	Proposed Sale	16.05	124,589	2,000,000		Nov 18 05:04 PM
Bensen Daniel	Chief Operating Officer	Nov 14 '25	Sale	16.02	110,228	1,765,489	316,642	Nov 17 07:03 PM
Bensen Daniel	Chief Operating Officer	Nov 17 '25	Sale	16.18	20,072	324,798	296,570	Nov 17 07:03 PM
Bensen Daniel	Chief Operating Officer	Nov 13 '25	Sale	16.00	1,111	17,780	426,870	Nov 17 07:03 PM
Daniel Bensen	Officer	Nov 17 '25	Proposed Sale	15.94	20,072	320,000		Nov 17 04:28 PM
Daniel Bensen	Officer	Nov 14 '25	Proposed Sale	15.98	86,339	1,380,000		Nov 14 04:29 PM
Daniel Bensen	Officer	Nov 13 '25	Proposed Sale	16.00	25,000	400,000		Nov 13 05:40 PM

RAIN

Rain Enhancement Technologies Holdco Inc

TNGX

Tango Therapeutics Inc

TYRA

Tyra Biosciences Inc

Upgrade your Finviz experience